Journal
CHEMMEDCHEM
Volume 18, Issue 15, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202300240
Keywords
fragment-based drug discovery; tuberculosis; dihydrofolate reductase; crystallography
Categories
Ask authors/readers for more resources
This study reports the preparation and evaluation of a series of compounds against Mycobacterium tuberculosis DHFR (MtbDHFR). Four compounds in this series showed high affinity against MtbDHFR, with sub-micromolar affinities. Protein crystallography was used to determine the binding mode of six of the best compounds, revealing occupation of an underutilised region of the active site.
Dihydrofolate reductase (DHFR) is a key enzyme involved in the folate pathway that has been heavily targeted for the development of therapeutics against cancer and bacterial and protozoa infections amongst others. Despite being an essential enzyme for Mycobacterium tuberculosis (Mtb) viability, DHFR remains an underexploited target for tuberculosis (TB) treatment. Herein, we report the preparation and evaluation of a series of compounds against Mtb DHFR (MtbDHFR). The compounds have been designed using a merging strategy of traditional pyrimidine-based antifolates with a previously discovered unique fragment hit against MtbDHFR. In this series, four compounds displayed a high affinity against MtbDHFR, with sub-micromolar affinities. Additionally, we determined the binding mode of six of the best compounds using protein crystallography, which revealed occupation of an underutilised region of the active site.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available